Cervical cancer: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 2
• PD-1 19
• PD-L1 12
• PI3K 3
• AKT 1
• CTLA-4 7
• HER2 9
• CTNNB1 0
• mTOR 0
• STAT3 0
• VEGF 3
• EGFR 2
• MAPK 0
• MYC 0
• PTEN 2
• NRF2 1
• PIK3CA 3
• ERK 0
• PARP 0
• AMPK 0
• JAK 0
• TROP2 4
• YAP 0
• BRCA1 2
• GPX4 0
• HIF-1 0
• IL-6 0
• TNF 0
• FOXP3 0
• KRAS 0
• B7-H3 3
• BCL-2 0
• BRCA2 2
• HER3 1
• JNK 0
• MMP-9 0
• STING 0
• STK11 0
• AXL 0
• CD47 0
• COX-2 0
• EZH2 0
• FAK 1
• HDAC 0
• HMGB1 0
• PPAR 0
• PRAME 0
• ATM 0
• CD40 0
• CXCR4 0
• IDH 1
• LAG-3 0
• METTL3 0
• NF1 0
• NOTCH1 0
• PKM2 0
• PRMT5 0
• SHP2 0
• SIRT1 0
• ALK 0

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Pembrolizumab and Olaparib in Cervical Cancer Patients

  NCT04483544· Baptist Health South Florida· Updated 29 Apr 2025

  “Poor accrual related to change in standard of care treatment for this population.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 28
• Organoids 10
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 21
• Gene Expression Profiling 68
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 17
• Metabolomics 9
• Mass Spectrometry 3
• Flow Cytometry 25
• Immunohistochemistry 46
• Liquid Biopsy 8
• Circulating Tumor DNA 6
• Xenograft Model Antitumor Assays 65
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 92
• Machine Learning 63
• Deep Learning 49
• Cohort Studies 81
• Genome-Wide Association Study 14

• Attentive interpretable tabular learning (TabNet) for miRNA expression classification in cervical cancer and Alzheimer's disease.

  BMC Bioinformatics, Oct 2026

• A hybrid deep learning framework for automated treatment planning in cervical cancer radiotherapy.

  J Appl Clin Med Phys, Oct 2026

• MCOD: a memory-constrained deep learning framework for robust outlier detection in quantitative proteomics.

  Brief Bioinform, Sept 2026

• Diagnostic performance of artificial intelligence models trained on scattered single-cell images is not preserved for hyperchromatic crowded cell groups in cervical cytology.

  Cancer Cytopathol, Sept 2026

• A Multimodal Graph Neural Network Based on MRI Radi-omics for Prognostic Prediction in Locally Advanced Cervical Squamous Cell Carcinoma.

  Cancer Control, Aug 2026

• From synthesis to clinic: a task-specific framework for CT images metal artifact reduction in cervical brachytherapy.

  Radiat Oncol, Aug 2026

• Enhanced Diagnosis of Cervical Cancer Using Archer Fish Hunting Optimizer-Optimized Xception Network with AI Interpretability via Grad-CAM.

  Asian Pac J Cancer Prev, Aug 2026

• A prospective development and evaluation of a 2D convolutional neural network-based auto-segmentation model for cervical cancer radiotherapy.

  J Egypt Natl Canc Inst, Jul 2026

• Deep learning reconstruction-applied PROPELLER diffusion-weighted imaging in uterine malignancies: a comparison study with MUSE.

  Jpn J Radiol, Jul 2026

• MedFusionNet: A hybrid transformer-based multimodal deep learning framework for chronic disease prediction in women's health.

  Comput Med Imaging Graph, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.